News >

Thoracic Oncologist Highlights Recent Pembrolizumab Data in NSCLC

Brandon Scalea
Published: Monday, Nov 19, 2018

Tracey L. Evans, MD

Tracey L. Evans, MD

Pembrolizumab (Keytruda) has emerged as an effective frontline treatment option for select patients with metastatic non–small cell lung cancer (NSCLC), explained Tracey L. Evans, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication